<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318028</url>
  </required_header>
  <id_info>
    <org_study_id>4P-19-4</org_study_id>
    <secondary_id>NCI-2019-05018</secondary_id>
    <secondary_id>4P-19-4</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT04318028</nct_id>
  </id_info>
  <brief_title>An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer</brief_title>
  <official_title>A Pilot Study of 7 Tesla MRI Neuroimaging Biomarkers of Prostate Cancer-Related Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies 7 Tesla magnetic resonance imaging (MRI) in diagnosing cognitive&#xD;
      impairment in patients with prostate cancer that has not spread to other places in the body&#xD;
      (non-metastatic) and who have or have not received androgen deprivation therapy (ADT). The&#xD;
      MRI machine uses a strong magnet and radio wave to make images of the inside of the body. A&#xD;
      stronger magnetic field allows greater signals and more detailed visualization of the&#xD;
      structure and function of human body. Giving 7 Tesla MRI may help doctors learn if patients&#xD;
      that receive ADT show more signs of cognitive dysfunction or brain fog compared to patients&#xD;
      to patients that do not receive ADT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Observe longitudinal changes in structural connectivity using T1-weighted and diffusion&#xD;
      tensor MRI in men with non-metastatic prostate cancer on current ADT versus those who were&#xD;
      not.&#xD;
&#xD;
      II. Observe longitudinal changes in brain functional connectivity using resting-state&#xD;
      functional (rsf) MRI.&#xD;
&#xD;
      III. Observe longitudinal changes in brain metabolic profiles evaluated by MR spectroscopy&#xD;
      (MRS).&#xD;
&#xD;
      IV. Exploratory assessment of correlation between testosterone and prostate specific antigen&#xD;
      (PSA) levels with MRI measures and cognitive measures.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the feasibility and acceptability of this approach using sequential 7T MRI in&#xD;
      prostate cancer patients either receiving ADT or not.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and at 6-9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Anticipated">August 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain structural connectivity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be measured using T1-weighted and diffusion tensor magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain functional connectivity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be measured using resting-state functional MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain metabolic profiles</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be evaluated by MR spectroscopy.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Assessment of testosterone and prostate specific antigen (PSA) levels</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>For the correlation of between testosterone and PSA levels with MRI measures and cognitive measures, the study will use scatter plots to explore the pattern of correlation. Spearmen's correlation will be used to test the correlation. Both groups will be combined for the correlation analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-Metastatic Prostate Carcinoma</condition>
  <condition>Stage I Prostate Cancer AJCC v8</condition>
  <condition>Stage II Prostate Cancer AJCC v8</condition>
  <condition>Stage IIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIC Prostate Cancer AJCC v8</condition>
  <condition>Stage III Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIA Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIB Prostate Cancer AJCC v8</condition>
  <condition>Stage IIIC Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Diagnostic (7 Tesla MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and 6-9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>7 Tesla Magnetic Resonance Imaging</intervention_name>
    <description>Undergo 7 Tesla MRI</description>
    <arm_group_label>Diagnostic (7 Tesla MRI)</arm_group_label>
    <other_name>7 Tesla MRI</other_name>
    <other_name>7T MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
          -  Group 1 (G1): Non-metastatic biopsy-proven prostate cancer patients on current ADT and&#xD;
&#xD;
          -  Group 2 (G2): Demographically (age, cancer stage) matched non-metastatic biopsy proven&#xD;
             prostate cancer patients without a history of ADT&#xD;
&#xD;
          -  Ability to undergo imaging procedure without any form of sedation&#xD;
&#xD;
          -  Ability to complete brief cognitive testing on iPad&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of dementia or other neuropsychiatric disease&#xD;
&#xD;
          -  History of other cancer medical therapies other than ADT, narcotics or psychiatric&#xD;
             medications&#xD;
&#xD;
          -  Standard contraindications for MRI:&#xD;
&#xD;
               -  Prior work as a machinist or metal worker, or history of metal being removed from&#xD;
                  the eyes,&#xD;
&#xD;
               -  Cardiac pacemaker or internal pacing wires,&#xD;
&#xD;
               -  Non-MRI compatible vena cava filter, vascular aneurysm clip, heart valve, spinal&#xD;
                  or ventricular shunt, optic implant, neuro-stimulator unit, ocular implant, or&#xD;
                  intrauterine device, or&#xD;
&#xD;
               -  Claustrophobia, or uncontrollable motion disorder&#xD;
&#xD;
          -  Currently active second malignancy&#xD;
&#xD;
          -  Any significant cardiovascular conditions (New York Heart Association [NYHA]) class&#xD;
             III or IV congestive heart failure, myocardial infarction within 6 months, unstable&#xD;
             angina, pacemaker); or&#xD;
&#xD;
          -  Renal disease with calculated creatinine clearance of &lt; 45 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S Shiroishi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhushan Desai</last_name>
    <phone>323-442-7469</phone>
    <email>Bhushan.Desai@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark S. Shiroishi</last_name>
      <phone>323-226-7425</phone>
      <email>Mark.Shiroishi@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark S. Shiroishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

